Company reports positive feedback from FDA meeting, paving the way towards IND for skin rejuvenation therapy.

Cell rejuvenation company Turn Biotechnologies has reported receiving positive feedback during an FDA INTERACT meeting to review the company’s therapeutic treatment to rejuvenate skin cells. The company, which is developing mRNA medicines for a range of age-related conditions, said that the meeting focused on its progress and plans for TRN-001, a treatment designed to repair damaged skin at the cellular level.

Turn Bio says its preclinical results demonstrate that TRN-001 improves skin integrity, reduces inflammation and cell senescence and achieves hair follicle transfection. If the therapy goes on to work in humans, the company claims it would be the first treatment to repair skin damage at a cellular level, restoring follicles’ ability to grow hair.

Following positive feedback at the INTERACT meeting, Turn Bio believes it is now “well positioned” to become the first company to take a cell rejuvenation therapy into clinical trials.

“We were gratified at the strong alignment between Turn Bio’s approach to developing TRN-001 and the comments of FDA reviewers,” said Anja Krammer, CEO of Turn Bio. “We look forward to advancing our pre-clinical work as we work toward IND submission.”

TRN-001 was developed using Turn Bio’s mRNA-based platform, which is designed to restore youthful function to cells. The platform aims to restore optimal gene expression by combatting the effects of aging in the epigenome and restoring cells’ ability to fight disease and regenerate tissue. The therapy is then delivered using the company’s proprietary lipid particle carrier system, which is designed to effectively deliver and target drugs to specific organs, tissues, and cell types in the body.

In addition to its work in dermatology, Turn Bio is conducting preclinical research on therapies targeting indications in immunology, and is also developing therapies for ophthalmology, osteo-arthritis, and the muscular system.